Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1987 2
1988 2
1989 3
1990 2
1991 3
1992 5
1993 7
1994 13
1995 3
1996 12
1997 8
1998 12
1999 8
2000 10
2001 15
2002 9
2003 20
2004 13
2005 17
2006 11
2007 10
2008 8
2009 10
2010 3
2011 5
2012 7
2013 8
2014 6
2015 9
2016 6
2017 3
2018 2
2019 3
2020 5
2021 6
2022 4
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J. Major P, et al. J Clin Oncol. 2001 Jan 15;19(2):558-67. doi: 10.1200/JCO.2001.19.2.558. J Clin Oncol. 2001. PMID: 11208851
RESULTS: Two hundred eighty-seven patients were randomized and evaluated for safety; 275 were evaluated for efficacy. Both doses of zoledronic acid were superior to pamidronate in the treatment of HCM. The complete response rates by day 10 were 88.4% (P = .002), 86. …
RESULTS: Two hundred eighty-seven patients were randomized and evaluated for safety; 275 were evaluated for efficacy. Both doses of zoledron …
Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K, Phillipi CA, Steiner RD, Basel D. Dwan K, et al. Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article. Review.
Two studies compared the intravenous bisphosphonates zoledronic acid and pamidronate. There were no significant differences in primary outcome. However, the studies were at odds as to the relative benefit of zoledronic acid over pamidronate for lumbosa …
Two studies compared the intravenous bisphosphonates zoledronic acid and pamidronate. There were no significant differences in …
Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis.
Bo Z, Jian Y, Yan L, Gangfeng G, Xiaojing L, Xiaolan L, Zhao C, Ke H, Yang F, Maoxia L, Jian W. Bo Z, et al. Oxid Med Cell Longev. 2022 Aug 18;2022:3511385. doi: 10.1155/2022/3511385. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36035203 Free PMC article. Review.
Pamidronate, prednisone, and levetiracetam ranked as the first three most effective treatments. ...Pamidronate and prednisone showed better effect than other pharmacotherapies, which warrants further investigation....
Pamidronate, prednisone, and levetiracetam ranked as the first three most effective treatments. ...Pamidronate and prednisone …
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Migliorini F, et al. J Orthop Surg Res. 2021 Aug 27;16(1):533. doi: 10.1186/s13018-021-02678-x. J Orthop Surg Res. 2021. PMID: 34452621 Free PMC article. Review.
Denosumab resulted in a higher spine BMD (SMD -0.220; SE 3.379), followed by pamidronate (SMD -5.662; SE 2.635) and zoledronate (SMD -10.701; SE 2.871). ...
Denosumab resulted in a higher spine BMD (SMD -0.220; SE 3.379), followed by pamidronate (SMD -5.662; SE 2.635) and zoledronate (SMD …
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Mhaskar R, et al. Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4. Cochrane Database Syst Rev. 2017. PMID: 29253322 Free PMC article. Review.
Data from nine observational studies (1400 participants) reported an incidence of 5% to 51% with combination of pamidronate and zoledronate, 3% to 11% with zoledronate alone, and 0% to 18% with pamidronate alone.The pooled results showed no evidence for a difference …
Data from nine observational studies (1400 participants) reported an incidence of 5% to 51% with combination of pamidronate and zoled …
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2015 Oct 3;386(10001):1353-1361. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Lancet. 2015. PMID: 26211824 Free article.
Primary subgroup investigations were site of first distant recurrence (bone or other), menopausal status (postmenopausal [combining natural and artificial] or not), and bisphosphonate class (aminobisphosphonate [eg, zoledronic acid, ibandronate, pamidronate] or othe …
Primary subgroup investigations were site of first distant recurrence (bone or other), menopausal status (postmenopausal [combining natural …
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T, Tesfamariam YM, Macherey S, Kuhr K, Adams A, Monsef I, Heidenreich A, Skoetz N. Jakob T, et al. Cochrane Database Syst Rev. 2020 Dec 3;12(12):CD013020. doi: 10.1002/14651858.CD013020.pub2. Cochrane Database Syst Rev. 2020. PMID: 33270906 Free PMC article.
Twenty-one trials could be considered in the quantitative analysis, of which six bisphosphonates (zoledronic acid, risedronate, pamidronate, alendronate, etidronate, or clodronate) were compared with each other, the RANKL-inhibitor denosumab, or no treatment/placebo …
Twenty-one trials could be considered in the quantitative analysis, of which six bisphosphonates (zoledronic acid, risedronate, pa …
Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis.
Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez Lloret A. Maccagno A, et al. Scand J Rheumatol. 1994;23(4):211-4. doi: 10.3109/03009749409103063. Scand J Rheumatol. 1994. PMID: 8091148 Clinical Trial.
Continuous oral pamidronate (APD), 1000 mg/day, was administered to 14 patients with rheumatoid arthritis. ...
Continuous oral pamidronate (APD), 1000 mg/day, was administered to 14 patients with rheumatoid arthritis. ...
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP, Coleman RE. Major PP, et al. Semin Oncol. 2001 Apr;28(2 Suppl 6):17-24. doi: 10.1016/s0093-7754(01)90261-1. Semin Oncol. 2001. PMID: 11346861 Review.
Corrected serum calcium normalization occurred by day 4 in 45.3% of patients treated with 4 mg zoledronic acid, 55.6% of patients treated with 8 mg zoledronic acid, and 33.3% of patients treated with pamidronate. Mean change from baseline in corrected serum c …
Corrected serum calcium normalization occurred by day 4 in 45.3% of patients treated with 4 mg zoledronic acid, 55.6% of patients tre …
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C, Mates M, Robinson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D; REaCT investigators. Clemons M, et al. Eur J Cancer. 2021 Jan;142:132-140. doi: 10.1016/j.ejca.2020.08.019. Epub 2020 Oct 3. Eur J Cancer. 2021. PMID: 33023785 Free PMC article. Clinical Trial.
RESULTS: Of 263 patients (160 breast cancer, 103 CRPC), 133 (50.6%) and 130 (49.4%) were randomised to the 4- and 12-weekly groups, respectively. BTAs included denosumab (56.3%), zoledronate (24.0%) and pamidronate (19.8%). Using repeated-measures analysis, across all time …
RESULTS: Of 263 patients (160 breast cancer, 103 CRPC), 133 (50.6%) and 130 (49.4%) were randomised to the 4- and 12-weekly groups, respecti …
255 results